Obeticholic Acid in Pediatric Subjects With Biliary Atresia

PHASE2TerminatedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

July 1, 2015

Primary Completion Date

March 9, 2023

Study Completion Date

March 9, 2023

Conditions
Biliary Atresia
Interventions
DRUG

OCA 0.1mg

Tablets administered orally once daily.

DRUG

OCA 1.5mg

Tablets administered orally once daily.

DRUG

OCA 5mg

Tablets administered orally once daily.

Trial Locations (17)

1200

Clinques University Saint-Luc, Brussels

10126

Regina Margherita Children's Hospital, Turin

13385

Hopital de la Timone, Marseille

24127

Centre for Paediatric Hepatology, Bergamo

30625

Hannover Medical School, Children's Hospital, Paediatric Gastroenterology and Hepatology,, Hanover

31059

CHU de Toulouse Purpan-Hopital des Enfants, Toulouse

59037

CHU Lille, Lille

75015

APHP- Hopital Necker Enfants Malades, Paris

84101

Soroka University Medical Center, Beersheba

91120

Hadassah Medical Center, Jerusalem

4920235

Schneider Children's Medical Center, Petah Tikva

9103102

Shaare-Zedek Medical Center, Jerusalem

9713 GZ

University Medical Center Gröningen-Beatrix, children's Hospital, Groningen

Unknown

Instytut Pomnik-Centrum Zdrowia Dziecka, Warsaw

Passeig Vall d'Hebron, Barcelona

Hospital Materno-Infantil de Malaga, Málaga

B4 6NH

Birmingham Children's Hospital, Birmingham

Sponsors
All Listed Sponsors
lead

Intercept Pharmaceuticals

INDUSTRY